The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

CSL and Arcturus Therapeutics have announced that Japan’s Ministry of Health, Labor and Welfare has granted approval for ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

Study reviews cardiovascular side effects linked to antiviral therapies for COVID-19, highlighting the need for careful ...

Researchers at multiple AViDD centers confirm that the NIH has offered a 1-year, no-cost extension, but it doesn’t come with ...

As I ran the National Institutes of Health during the pandemic, I learned that something deep within our culture is wrong.

Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (NASDAQ: CRSP), Gilead Sciences (NASDAQ: GILD), and ...

Researchers studied more than 1,000 people living with this syndrome to find out this top long COVID symptom. They found that ...

Moderna (NYSE: MRNA) stock plunged Thursday on news it will be slashing its research and development budget by about 20% over ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Australian biotechnology company CSL Ltd. (CSL.AX, CSLLY.PK) and sa-mRNA pioneer Arcturus Therapeutics (ARCT), announced Friday that ...

King of Prussia, Pennsylvania Monday, September 16, 2024, 17:00 Hrs [IST] ...